Breast Cancer Breakthroughs Episode 17: What's New in Metastatic HER2+ Breast Cancer?

HER2-positive breast cancer is aggressive, but research and clinical trials have transformed it from one of the most difficult to treat cancers to one with many options. However, resistance to current treatments still occurs. In this episode of Breast Cancer Breakthroughs, we’ll hear from Komen Scholar Alumni Ian Krop, M.D., Ph.D., Komen Scholar Sara Tolaney, M.D., MPH, and patient advocate Susan Koegel as they talk about some of the latest progress and investigational studies for patients with metastatic HER2-positive breast cancer.  This video is intended and approved for U.S. audiences. Speakers: -Kelsey Hampton, PhD, is Director, Mission Communications & Education at Susan G. Komen -Ian Krop, M.D., Ph.D. is a medical oncologist at Yale University School of Medicine -Sara Tolaney, MD, MPH, is a medical oncologist at Dana-Farber Cancer Institute. -Susan Koegel is Co-Lead of the Dana-Farber Cancer Institute Breast Cancer Research Advocacy Group Primary Links: -Sign up for reminders about future episodes of Breast Cancer Breakthroughs here: https://www.komen.org/about-komen/our... -Link to Survey: https://susangkomen.iad1.qualtrics.co... -Clinical Trial Finder: https://www.breastcancertrials.org/BC... Videos: -What is Treatment Resistance?    • What is treatment resistance?   -HER2: A Driver of Breast Cancer:    • HER2: A Driver of Breast Cancer   -HER2-Targeted Therapies:    • HER2 Targeted Therapies   Additional Resources: -HER2 Status: https://www.komen.org/breast-cancer/d... HER2-Positive Breast Cancer: From Diagnosis and Treatment to Monitoring: https://www.komen.org/blog/know-more-... Contents of a Pathology Report – HER2: https://www.komen.org/breast-cancer/d... -HER2-Targeted Therapies for Metastatic Breast Cancer: https://www.komen.org/breast-cancer/m... -Shining a Spotlight on More Effective Treatments for HER2+ MBC: https://www.komen.org/blog/empowher-3... Clinical Trials Mentioned in Episode: -DESTINY-Breast09 (Active, not recruiting) NCT04784715: https://clinicaltrials.gov/study/NCT0... PATINA (Active, not recruiting) NCT02947685: https://clinicaltrials.gov/study/NCT0... EmpowHER 303 (Active, recruiting) NCT06435429: https://clinicaltrials.gov/study/NCT0... Spotlight on Clinical Trials: EmpowHER 303: https://www.komen.org/wp-content/uplo... Please keep in mind for some of our channel content, closed captions are auto-generated. 00:00 Introduction 01:19 Background on HER2+ Breast Cancer 02:44 Testing, Diagnosis and Treatment of HER2+ Breast Cancer 08:17 DESTINY-Breast09 and PATINA Clinical Trials 11:22 EmpowHER 303 Clinical Trial 14:18 Final Remarks on the Future of Metastatic HER2+ Breast Cancer 18:57 Conclusion